


Stabilis



Oseltamivir



Stabilité des préparations

| | | 450 mg Tamiflu® | Sirop de cerise >> 30 ml | 23-27°C | | 5 | | | 2692 |
|--|--|-----------------|----------------------------|---------|--|----|--|--|------|
| | | 450 mg Tamiflu® | Orasweet SF® >> 30 ml | 28-32°C | | 13 | | | 2692 |
| | | 450 mg Tamiflu® | Sirop de cerise >> 30 ml | 3-7°C | | 35 | | | 2692 |
| | | 450 mg Tamiflu® | Orasweet SF® >> 30 ml | 3-7°C | | 35 | | | 2692 |
| | | 375 mg Tamiflu® | Sirop de cerise >> 25 ml | 2-8°C | | 30 | | | 3090 |
| | | 375 mg Tamiflu® | SyrSpend SF® >> 25 ml | 2-8°C | | 30 | | | 3090 |
| | | 375 mg Tamiflu® | SyrSpend SF® >> 25 mL | 2-8°C | | 90 | | | 3996 |
| | | 900 mg ® = ? | SyrSpend SF PH4® >> 150 ml | 2-8°C | | 90 | | | 4177 |
| | | 450 mg Tamiflu® | Sirop de cerise >> 30 ml | 23-27°C | | 5 | | | 2692 |
| | | 450 mg Tamiflu® | Orasweet SF® >> 30 ml | 28-32°C | | 13 | | | 2692 |
| | | 450 mg Tamiflu® | Sirop de cerise >> 30 ml | 3-7°C | | 35 | | | 2692 |
| | | 450 mg Tamiflu® | Orasweet SF® >> 30 ml | 3-7°C | | 35 | | | 2692 |



Bibliographie

| | Type | Source |
|------|-------|--|
| 2692 | Revue | Winiarski AP, Infeld MH, Tscherne R, Bachinsky M, Rucki R, Nagano-Mate K. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. J Am Pharm Assoc 2007 ; 47, 6; 747-755. |
| 3090 | Revue | Voudrie MA, Brett Allen D. Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup, and SyrSpend SF (For Reconstitution). Int J Pharm Compound 2010 ; 14, 1: 82-85. |
| 3996 | Revue | Dijkers E, Nanhekhan V, Thorissen A. Updated Stability Data of Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSpend SF and Minoxidil in Espumil. Int J Pharm Compound 2017 ; 21,3 : 240-241. |
| 4177 | Revue | Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526 |



Dictionnaire

| | |
|--|--|
|  Antiviral |  Solution buvable |
|  Stabilité des préparations |  Contenant |
|  Origine |  Excipient |
|  Température |  Conservation |
|  Durée de stabilité |  Biosimilaire |
|  Données conflictuelles |  Bibliographie |
|  Verre |  Gélules |
|  A l'abri de la lumière |  Jour |
|  Flacon plastique |  Non précisée |
|  Comprimés |  Poudre |
|  Bibliographie |  Dictionnaire |